Clinical trials: Pulmonary Hypertension, pill or tablet or capsule or oral, open to volunteers
- Condition Pulmonary Hypertension
- Drug or intervention pill OR tablet OR capsule OR oral
- Status Open to volunteers
Pulmonary Arterial Hypertension (PAH)
Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by increased pressure in the pulmonary arteries, leading to right heart failure and premature death.
- Trial name
- ASCEND-PAH (NCT07713914)
- Testing
- Prostacyclin Pathway Agent, Sildenafil Dose Optimization
- Where
- Brazil
- Volunteers
- 196 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension
Spironolactone for Pulmonary Arterial Hypertension
Background: High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate remains unacceptably high.
- Trial name
- NCT01712620
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension (PAH)
imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
Pulmonary arterial hypertension (PAH) is a progressive condition with high morbidity, frequent hospitalizations, and risk of right heart failure. Despite advances in treatment, poor adherence remains a major challenge.
- Conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension
- Trial name
- OPENLINE (NCT06850792)
- Testing
- Telemedicine-Based Adherence Support
- Where
- Brazil
- Volunteers
- 61 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Artery Hypertension, Vitamin d Deficiency
REstoration of VItamin D in Pulmonary Arterial Hypertension
Background. Pulmonary arterial hypertension (PAH) is a heterogeneous pathophysiological condition characterized by progressive pulmonary vascular narrowing that ultimately results in right-sided heart failure and eventually death…
- Trial name
- REVIDAH (NCT06258850)
- Testing
- Calcifediol Oral Capsule
- Volunteers
- 102 people
- Sponsor
- Parc de Salut Mar
Intrahepatic Cholangiocarcinoma (Icc), Liver Injury
Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury
The goal of this study is to find out whether phycocyanin, a natural protein from spirulina, can help protect the liver and support recovery in adults having part of their liver removed.
- Trial name
- NCT07760038
- Testing
- Phycocyanin, Maltodextrin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pulmonary Arterial Hypertension
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
TripleTRE investigates the effect of initial triple combination therapy (oral endothelin receptor antagonist (ERA) + oral phosphodiesterase tyüe-5 inhibitor (PDE-5i) + parenteral treprostinil) compared to double oral therapy…
- Trial name
- TripleTRE (NCT06317805)
- Testing
- Generic treprostinil sodium + Standard of Care (Double Oral), Standard of Care - Double Oral
- Where
- 28 sites in Argentina, Austria and 10 more
- Volunteers
- 110 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension PAH
- Trial name
- TRANSCEND (NCT07612657)
- Testing
- VI-0106
- Volunteers
- 300 people
- Sponsor
- VIVUS LLC
Pulmonary Hypertension
Colchicine in Pulmonary Artery Hypertension Patients
This study evaluates the efficacy of colchicine in improving cardiopulmonary function for patients diagnosed with Pulmonary Arterial Hypertension (PAH), a condition characterized by elevated pulmonary pressure that impairs right…
- Trial name
- NCT07907757
- Testing
- Colchicine 0.5 MG Oral Tablet
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Pulmonary Arterial Hypertension
A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
The goal of this clinical trial is to learn if empagliflozin works to treat patients with pulmonary arterial hypertension. It will also learn about the safety of empagliflozin.
- Trial name
- NCT06554301
- Testing
- empagliflozin in treatment pulmonary aerterial hypertension
- Where
- China
- Volunteers
- 72 people
- Sponsor
- China National Center for Cardiovascular Diseases
Pulmonary Hypertension Associated With HFpEF
Long-Term Open-Label Extension Study of Oral Levosimendan
The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with…
- Trial name
- NCT07436689
- Testing
- TNX-103
- Where
- 10 sites in United States
- Volunteers
- 800 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Hypertension
Preliminary Human Trials of F230 Tablets
F230 is a new Class 1 chemical drug jointly developed by Beijing Contini Pharmaceutical Co., Ltd. for the treatment of pulmonary hypertension (Notification number: 2024LP01242, 2024LP01243).
- Trial name
- NCT06899815
- Testing
- F230 tablets
- Where
- China
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Persistent Pulmonary Hypertension of Newborn
Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn
The aim of this study is to evaluate the effectiveness of nebulized magnesium sulfate combined with sildenafil citrate, compared with sildenafil citrate alone, in treating neonates with severe persistent pulmonary hypertension on…
- Trial name
- NCT04898114
- Testing
- Magnesium sulfate, Sildenafil Citrate, Isotonic saline
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sohag University
Pulmonary Arterial Hypertension (PAH)
Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension
This is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled clinical trial.
- Trial name
- ALEPH (NCT06987097)
- Testing
- Ambrisentan
- Volunteers
- 410 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pulmonary Arterial Hypertension
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.
- Trial name
- EmPATH (NCT06992440)
- Testing
- Empagliflozin 10 MG
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- Gustavo A Heresi, MD, MS
Pulmonary Hypertension Due to Lung Diseases and Hypoxia
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD).
- Trial name
- NCT05798923
- Testing
- LAM-001
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- IRulya Therapeutics Inc.
BPD - Bronchopulmonary Dysplasia, Pulmonary Hypertension
Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC
The purpose of this study is to evaluate the safety and explore the PK/PD of L-CIT supplementation in preterm infants to prevent the development of inflammatory pathways initiated by low levels of plasma CIT, specifically in…
- Conditions
- BPD - Bronchopulmonary Dysplasia, Pulmonary Hypertension, NEC
- Trial name
- NCT05636397
- Testing
- L-Citrulline
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- The Hospital for Sick Children
Erythrocytosis, Pulmonary Hypertension
Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis
Some people develop erythrocytosis, a condition characterized by having too many red blood cells, because of inherited changes (mutations) in genes such as EPAS1, EGLN1, or VHL.
- Conditions
- Erythrocytosis, Pulmonary Hypertension, Thrombosis
- Trial name
- NCT07895966
- Testing
- Belzutifan
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Utah
Pulmonary Hypertension, Hypertension, Pulmonary Arterial
Real-World Study of PADN for the Treatment of PAH
Real-World Study of PADN for the Treatment of PAH
- Trial name
- NCT07039604
- Testing
- Enhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Pulnovo Medical (Wuxi) Co., Ltd.
Pulmonary Arterial Hypertension
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
- Trial name
- NCT06274801
- Testing
- Seralutinib, Gereic Dry Powder Inhaler
- Where
- 120 sites in United States, Argentina and 28 more
- Volunteers
- 330 people
- Sponsor
- Gossamer Bio USA, Inc.
Chronic Thromboembolic Pulmonary Hypertension
Switching of Sildenafil to Riociguat in CTEPH Patients
This study was designed to investigate the safety and efficacy of replacing phosphodiesterase 5 inhibitors (PDE5i) with riociguat in patients with Chronic thromboembolic pulmonary hypertension (CTEPH) who have undergone pulmonary…
- Trial name
- S2R (NCT06715280)
- Testing
- Riociguat (Adempas)
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong